Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Office of health affairs dissolves

This article was originally published in The Gray Sheet

Executive Summary

Professional staff members from the FDA Center for Devices and Radiological Health's office of health affairs are reassigned to positions in the office of standards and regulations and the office of device evaluation following the dissolution of OHA. OHA Deputy director Thomas Arrowsmith-Lowe, MD, and staffers Peter Paras and Robert Gottesman have moved to OSR. Four staffers have moved to ODE: Kevin Mulry, DDS, to the division of general and restorative devices; Claudia Gaffey, MD, to the division of clinical laboratory devices; and Mariana Kastrinakis, MD, and Suzanne Parisian, MD, to the division of reproductive, abdominal, ENT and radiological devices. OHA Director Gordon Johnson, MD, has retired.

You may also be interested in...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts